SSP
SVA

Sapphire Star Partners’s Sinovac Biotech, Ltd SVA Stock Holding History

Sapphire Star Partners’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$722K Buy
104,014
+3,294
+3% +$24.1K 0.97% 33
2018
Q3 		$772K Buy
100,720
+3,728
+4% +$26.9K 0.77% 45
2018
Q2 		$723K Buy
+96,992
New +$763K 0.75% 53

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return

Sapphire Star Partners's SVA Position: Q4 2018 in Review

Sapphire Star Partners increased its Sinovac Biotech, Ltd (SVA) stake by 3.3% in Q4 2018, buying an estimated $24.1K and bringing the position to 104,014 shares worth $722K. The position accounts for 0.97% of the portfolio, ranked #33.

Sapphire Star Partners first reported a position in SVA in Q2 2018 and has held it in 3 quarters since. The position peaked at $772K in Q3 2018. 27 funds tracked by Wall St. Rank hold SVA as of Q4 2018.

  • Sapphire Star Partners held 104,014 shares of Sinovac Biotech, Ltd worth $722K as of Q4 2018.
  • Sapphire Star Partners bought 3,294 Sinovac Biotech, Ltd shares in Q4 2018, an estimated $24.1K.
  • Sinovac Biotech, Ltd made up 0.97% of Sapphire Star Partners's portfolio in Q4 2018, its #33 holding.
  • Sapphire Star Partners first reported a position in Sinovac Biotech, Ltd in Q2 2018 and has held it in 3 quarters since.
  • Sapphire Star Partners's Sinovac Biotech, Ltd position peaked at $772K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2018.

Based on Sapphire Star Partners's 13F filing for Q4 2018, filed 12 Feb 2019.